Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M151,772Revenue $M11,202Net Margin (%)45.5Z-Score8.9
Enterprise Value $M155,163EPS $1.8Operating Margin %58.6F-Score8
P/E(ttm))17.7Cash Flow Per Share $4.3Pre-tax Margin (%)56.7Higher ROA y-yY
Price/Book11.210-y EBITDA Growth Rate %0Quick Ratio1.8Cash flow > EarningsY
Price/Sales8.15-y EBITDA Growth Rate %8.2Current Ratio2.1Lower Leverage y-yN
Price/Cash Flow17.4y-y EBITDA Growth Rate %176ROA % (ttm)35.3Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)72.0Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M1,512ROI % (ttm)15.0Gross Margin Increase y-yY

Gurus Latest Trades with GILD

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GILDRonald Muhlenkamp 2014-09-30 Add1.19%$85.07 - $109.43
($97.98)
$ 100.583%Add 42.59%206,350
GILDJoel Greenblatt 2014-09-30 Add0.21%$85.07 - $109.43
($97.98)
$ 100.583%Add 42.28%664,223
GILDDavid Dreman 2014-09-30 Buy 0.02%$85.07 - $109.43
($97.98)
$ 100.583%New holding, 2388 sh.2,388
GILDJohn Burbank 2014-09-30 Add0.01%$85.07 - $109.43
($97.98)
$ 100.583%Add 219.9%12,073
GILDDodge & Cox 2014-09-30 Buy $85.07 - $109.43
($97.98)
$ 100.583%New holding, 4800 sh.4,800
GILDKen Heebner 2014-09-30 Reduce-0.33%$85.07 - $109.43
($97.98)
$ 100.583%Reduce -8.77%1,560,000
GILDVanguard Health Care Fund 2014-09-30 Reduce-0.28%$85.07 - $109.43
($97.98)
$ 100.583%Reduce -76.79%379,200
GILDRay Dalio 2014-09-30 Reduce-0.07%$85.07 - $109.43
($97.98)
$ 100.583%Reduce -30.96%241,521
GILDKen Fisher 2014-09-30 Reduce-0.04%$85.07 - $109.43
($97.98)
$ 100.583%Reduce -21.74%763,423
GILDKen Heebner 2014-06-30 Buy 3.8%$65.48 - $83.02
($77.76)
$ 100.5829%New holding, 1710000 sh.1,710,000
GILDJulian Robertson 2014-06-30 Add2.98%$65.48 - $83.02
($77.76)
$ 100.5829%Add 28.55%443,911
GILDJoel Greenblatt 2014-06-30 Buy 0.48%$65.48 - $83.02
($77.76)
$ 100.5829%New holding, 466853 sh.466,853
GILDJohn Rogers 2014-06-30 Add0.25%$65.48 - $83.02
($77.76)
$ 100.5829%Add 60.78%638,734
GILDKen Fisher 2014-06-30 Add0.07%$65.48 - $83.02
($77.76)
$ 100.5829%Add 62.11%975,483
GILDRay Dalio 2014-06-30 Add0.06%$65.48 - $83.02
($77.76)
$ 100.5829%Add 41.22%349,821
GILDRonald Muhlenkamp 2014-06-30 Reduce-0.59%$65.48 - $83.02
($77.76)
$ 100.5829%Reduce -24.63%144,715
GILDVanguard Health Care Fund 2014-06-30 Reduce-0.21%$65.48 - $83.02
($77.76)
$ 100.5829%Reduce -39.79%1,633,700
GILDGeorge Soros 2014-06-30 Sold Out -0.04%$65.48 - $83.02
($77.76)
$ 100.5829%Sold Out0
GILDMariko Gordon 2014-06-30 Reduce-0.02%$65.48 - $83.02
($77.76)
$ 100.5829%Reduce -35.57%11,654
GILDJulian Robertson 2014-03-31 Add0.59%$68.55 - $83.95
($78.44)
$ 100.5828%Add 7.91%345,320
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GILD is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
GILD David Dreman 2014-09-302,38800.02New Buy
GILD Dodge & Cox 2014-09-304,80000New Buy
GILD John Burbank 2014-09-3012,07300.02+219.9%
GILD Ronald Muhlenkamp 2014-09-30206,3500.014+42.59%
GILD Joel Greenblatt 2014-09-30664,2230.040.7+42.28%
GILD John Rogers 2014-09-30643,8960.040.88+0.81%
GILD Julian Robertson 2014-09-30443,9110.0312.5
GILD Jean-Marie Eveillard 2014-09-3040000
GILD Ken Heebner 2014-09-301,560,0000.14.7-8.77%
GILD Mariko Gordon 2014-09-3010,36600.05-11.05%
GILD Mario Gabelli 2014-09-3042,60000.02-13.36%
GILD Ken Fisher 2014-09-30763,4230.050.17-21.74%
GILD Ray Dalio 2014-09-30241,5210.020.2-30.96%
GILD Vanguard Health Care Fund 2014-09-30379,2000.030.1-76.79%
Premium Most recent portfolio changes are included for Premium Members only!


GILD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MILLIGAN JOHN FPresident and COO 2014-11-07Sell146,895$107.37-6.32view
Whitley Richard JamesDirector 2014-11-03Sell5,000$112.02-10.21view
Washington Robin LEVP, CFO 2014-11-03Sell33,192$110.26-8.78view
Alton Gregg HEVP, Corp & Med Affairs 2014-11-03Sell33,000$110.5-8.98view
Carter Paul RutherfordEVP Commercial Ops 2014-11-03Sell3,000$112.46-10.56view
MARTIN JOHN CChairman and CEO 2014-11-03Sell140,625$110.4-8.89view
Carter Paul RutherfordEVP Commercial Ops 2014-10-24Sell2,000$110-8.56view
Cogan John FrancisDirector 2014-10-21Sell15,000$104.08-3.36view
MILLIGAN JOHN FPresident and COO 2014-10-07Sell146,895$104.6-3.84view
Whitley Richard JamesDirector 2014-10-01Sell5,000$106.99-5.99view

Press Releases about GILD :

Quarterly/Annual Reports about GILD:

News about GILD:

Articles On GuruFocus.com
Weekly CFO Sells Highlight: Tableau Software Inc, Gilead Sciences Inc, Facebook Inc. Nov 16 2014 
Gilead Sciences Releases Impressive Results for Hepatitis C Drug Nov 12 2014 
Gilead Sciences Can Sustain Its Impressive Performance in the Long Run Nov 11 2014 
Why Gilead Sciences' Bull Run Should Continue Nov 06 2014 
Three Attractively Priced Small Cap Biotech Stocks Nov 05 2014 
Gilead Sciences has Multiple Growth Drivers Oct 31 2014 
Is Gilead Sciences a Worthy Investment? Oct 30 2014 
Gilead Sciences – From The Long Term Perspective Oct 08 2014 
There's More to Gilead Sciences than a Successful Drug Sep 26 2014 
A Few Reasons Why AbbVie's Momentum Will Continue Sep 25 2014 


More From Other Websites
Hedge funds playing buy-and-hold, and losing Nov 24 2014
Good Week for Gilead's Hepatitis-C Treatments, UBS Says Nov 21 2014
AbbVie, Celgene, Sanofi Drugs Get EU Endorsements Nov 21 2014
Gilead to Buy Knight Therapeutics' Priority Review Voucher Nov 20 2014
Ooh La La: France Negotiates a Steep Discount for Sovaldi From Gilead Nov 20 2014
France pegs Gilead hepatitis C drug at "lowest price in Europe" Nov 20 2014
Gilead Gains on Harvoni's EU Approval for HCV Treatment Nov 19 2014
How Much? Gilead Pays $125M For an FDA Priority Review Voucher Nov 19 2014
Gilead Sciences: The Worst Case Scenario? Nov 19 2014
Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in the EU Nov 19 2014
The Buzziest Biotech Stocks on Social Media Nov 18 2014
Stock Movers: Why 4 Big Drug Stocks Are Rising Today Nov 18 2014
Gilead Sciences: Harvoni Gets European Marketing OK Nov 18 2014
Gilead Sciences (GILD) Stock Rises After European Commission Market Authorization for Harvoni Nov 18 2014
European Commission Grants Marketing Authorization for Gilead’s Harvoni®?... Nov 18 2014
European Commission Grants Marketing Authorization for Gilead’s Harvoni®▼... Nov 18 2014
GILEAD SCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a... Nov 17 2014
Incyte Building Blockbuster Drug One Disease At A Time Nov 17 2014
Gilead: What About Its Pipeline? Nov 17 2014
Biotech Stocks Hit: Stock Market To See New Leaders? Nov 14 2014

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK